Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, Patrick K. Mitchell, Malini B. DeSilva, Stephanie A. Irving, Ned Lewis, Karthik Natarajan, Edward Stenehjem, Shaun J. Grannis, Jungmi Han, Charlene McEvoy, Toan C. Ong, Allison L. Naleway, Sarah E. Reese, Peter J. Embí, Kristin Dascomb, Nicola P. Klein, Eric P. Griggs, Deepika Konatham, Anupam B. Kharbanda, Duck‐Hye Yang, William F. Fadel, Nancy Grisel, Kristin Goddard, Palak Patel, I‐Chia Liao, Rebecca Birch, Nimish R. Valvi, Sue Reynolds, Julie Arndorfer, Ousseny Zerbo, Monica Dickerson, Kempapura Murthy, Jeremiah Williams, Catherine H. Bozio, Lenee Blanton, Jennifer R. Verani, Stephanie J. Schrag, Alexandra F. Dalton, Mehiret H. Wondimu, Ruth Link‐Gelles, Eduardo Azziz‐Baumgartner, Michelle A. Barron, Manjusha Gaglani, Mark G. Thompson, Bruce Fireman
MMWR Morbidity and Mortality Weekly Report
February 11, 2022
10.15585/mmwr.mm7107e2
Cited by 472Open Access
Full Text

Abstract

Persons categorized as having received 3 doses included those who received a third dose in a primary series or a booster dose after a 2 dose primary series (including the reduced-dosage Moderna booster). The VISION Network analyzed 241,204 ED/UC encounters** and 93,408 hospitalizations across 10 states during August 26, 2021-January 22, 2022. VE after receipt of both 2 and 3 doses was lower during the Omicron-predominant than during the Delta-predominant period at all time points evaluated. During both periods, VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination. During the Omicron period, VE against ED/UC visits was 87% during the first 2 months after a third dose and decreased to 66% among those vaccinated 4-5 months earlier; VE against hospitalizations was 91% during the first 2 months following a third dose and decreased to 78% ≥4 months after a third dose. For both Delta- and Omicron-predominant periods, VE was generally higher for protection against hospitalizations than against ED/UC visits. All eligible persons should remain up to date with recommended COVID-19 vaccinations to best protect against COVID-19-associated hospitalizations and ED/UC visits.

Related Papers

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof, Jeff Slezak, Heidi Fischer et al.|The Lancet|2021|1.3k
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda, Noa Dagan, Cyrille J. Cohen et al.|The Lancet|2021|940
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
Emma K. Accorsi, Amadea Britton, Katherine E. Fleming-Dutra et al.|JAMA|2022|682
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
Mark G. Thompson, Edward Stenehjem, Shaun J. Grannis et al.|New England Journal of Medicine|2021|500
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark G. Thompson, Karthik Natarajan, Stephanie A. Irving et al.|MMWR Morbidity and Mortality Weekly Report|2022|429